소아 아토피피부염의 최신 치료

키워드

참고문헌 (50)

1. Park YM, "Risk factors of atopic dermatitis in Korean schoolchildren : 2010 international study of asthma and allergies in childhood", Asian Pac J Allergy Immunol, 34, pp.65~72 (2016)
2. Investigation of the reference ranges of respiratory and allergic diseases test based on disease diagnosis in nationwide randomized general pediatric population, "Korea Centers for Disease Control and Prevention (KCDC)", KCDC, ~ (2015)
3. Kage P, "Atopic dermatitis and psychosocial comorbidities-What's new", Allergol Select, 4, pp.86~96 (2020)
4. Czarnowicki T, "Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march", J Allergy Clin Immunol, 139, pp.1723~1734 (2017)
5. Korean Academy of Pediatric Allergy and Respiratory Disease, "Pediatric allergy pulmonology & immunology", pp.191~219 (2013), Yeomungak
6. Katoh N, "Japanese guidelines for atopic dermatitis 2020", Allergol Int, 69, pp.356~369 (2020)
7. Hanifin JM, "Diagnostic features of atopic dermatitis", Acta Dermatol Venerol(Stockh), 92, pp.44~47 (1980)
8. Eichenfield LF, "Consensus conference on pediatric atopic dermatitis", J Am Acad Dermatol, 49, pp.1088~1095 (2003)
9. Korean Academy of Pediatric Allergy and Respiratory Disease, "Guideline for pediatric atopic dermatitis", pp.17~30 (2008), Gwangmun
10. Wollenberg A, "ETFAD", EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children, 2020, pp.34, 2717~2744
11. Oranje AP, "Practical issues on interpretation of scoring atopic dermatitis : the SCORAD index, objective SCORAD and the three-item severity score", Br J Dermatol, 157, pp.645~648 (2007)
12. Chopra R, "Severity strata for Eczema Area and Severity Index(EASI), modified EASI, Scoring Atopic Dermatitis(SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis", Br J Dermatol, 177, pp.1316~1321 (2017)
13. 김정은, "2019 Consensus Korean Diagnostic Guidelines to Define Severity Classification and Treatment Refractoriness for Atopic Dermatitis: Objective and Subjective Assessment of Severity", Annals of Dermatology, 31(6), pp.654~661 (2019), 대한피부과학회[DOI]
14. Leshem YA, "What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis : an interpretability study", Br J Dermatol, 172, pp.1353~1357 (2015)
15. Chopra R, "Assessing the severity of atopic dermatitis in clinical trials and practice", Clin Dermatol, 36, pp.606~615 (2018)
16. Boguniewicz M, "Expert perspectives on management of moderate-to-severe atopic dermatitis : a multidisciplinary consensus addressing current and emerging therapies", J Allergy Clin Immunol Pract, 5, pp.1519~1531 (2017)
17. 조중범, "아토피피부염의 중증도 변화에 따른 삶의 질 변화", Allergy Asthma & Respiratory Disease, 22(1), pp.86~99 (2012), 대한 소아알레르기 호흡기학회[DOI]
18. Thijs J, "Biomarkers for atopic dermatitis : a systematic review and meta-analysis", Curr Opin Allergy Clin Immunol, 15, pp.453~460 (2015)
19. Thijs JL, "A panel of biomarkers for disease severity in atopic dermatitis", Clin Exp Allergy, 45, pp.698~701 (2015)
20. Brunner PM, "The immunology of atopic dermatitis and its reversibility with broad–spectrum and targeted therapies", J Allergy Clin Immunol, 139, pp.65~76 (2017)
21. Fujita H, "Human Langerhans cells induce distinct IL-22-producing CD4þ T cells lacking IL-17 production", Proc Natl Acad Sci U S A, 106, pp.21795~21800 (2009)
22. Hammad H, "Barrier epithelial cells and the control of type 2 immunity", Immunity, 43, pp.29~40 (2015)
23. Doreen Siegels, "Systemic treatments in the management of atopic dermatitis: A systematic review and meta‐analysis", Allergy, 76(4), pp.1053~1076 (2021), Wiley[DOI]
24. 김정은, "Consensus Guidelines for the Treatment of Atopic Dermatitis in Korea (Part I): General Management and Topical Treatment", Annals of Dermatology, 27(5), pp.563~577 (2015), 대한피부과학회
25. Wollenberg A, "Consensus-based European guidelines for treatment of atopic eczema(atopic dermatitis)in adults and children : part I", J Eur Acad Dermatol Venereol, 32, pp.657~682 (2018)
26. Barnes PJ, "Molecular mechanisms of corticosteroids in allergic diseases", Allergy, 56, pp.928~936 (2001)
27. Glass CK, "Combinatorial roles of nuclear receptors in inflammation and immunity", Nat Rev Immunol, 6, pp.44~55 (2006)
28. Ali MA, "Topical steroid therapy induces pro-tolerogenic changes in Langerhans cells in human skin", Immunology, 146, pp.411~422 (2015)
29. Feldmann RJ, "Regional variation in percutaneous penetration of 14C cortisol in man", J Invest Dermatol, 48, pp.181~183 (1967)
30. Caproni M, "The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis : an immunohistochemical study", Br J Dermatol, 156, pp.312~319 (2007)
31. Nakahara T, "Mechanistic insights into topical tacrolimus for the treatment of atopic dermatitis", Pediatr Allergy Immunol, 29, pp.233~238 (2018)
32. Remitz A, "Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children", Acta Derm Venereol, 87, pp.54~61 (2007)
33. Fahrbach K, "Crisaborole ointment, 2%, for treatment of patients with mild-to-moderate atopic dermatitis : systematic literature review and network meta-analysis", Dermatol Ther(Heidelb), 10, pp.681~694 (2020)
34. 염혜영, "Current Management of Moderate-to-Severe Atopic Dermatitis: A Survey of Allergists, Pediatric Allergists and Dermatologists in Korea", Allergy, Asthma & Immunology Research, 10(3), pp.253~259 (2018), 대한천식알레르기학회
35. Wollenberg A, "Consensus-based European guidelines for treatment of atopic eczema(atopic dermatitis)in adults and children : part II", J Eur Acad Dermatol Venereol, 32, pp.850~878 (2018)
36. Schmitt J, "Cyclosporin in the treatment of patients with atopic eczema-a systematic review and meta-analysis", J Eur Acad Dermatol Venereol, 21, pp.606~619 (2007)
37. Harper JI, "Cyclosporin for severe childhood atopic dermatitis : short course versus continuous therapy", Br J Dermatol, 142, pp.52~58 (2000)
38. Caufield M, "Oral azathioprine for recalcitrant pediatric atopic dermatitis : clinical response and thiopurine monitoring", J Am Acad Dermatol, 68, pp.29~35 (2013)
39. Murphy LA, "A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression", Br J Dermatol, 147, pp.308~315 (2002)
40. Berth-Jones J, "Azathioprine in severe adult atopic dermatitis : a double-blind, placebo-controlled, crossover trial", Br J Dermatol, 147, pp.324~330 (2002)
41. Phan K, "Mycophenolate mofetil and atopic dermatitis : systematic review and meta-analysis", J Dermatolog Treat, 31, pp.810~814 (2020)
42. El-Khalawany MA, "Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children : a multicenter experience from Egypt", Eur J Pediatr, 172, pp.351~356 (2013)
43. Paller AS, "Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis : a randomized, double-blinded, placebo-controlled phase 3 trial", J Am Acad Dermatol, 83, pp.1282~1292 (2020)
44. Szegedi K, "Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin", J Eur Acad Dermatol Venereol, 29, pp.2136~2144 (2015)
45. Guttman-Yassky E, "Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis : a phase 2b randomized clinical trial", JAMA Dermatol, 156, pp.411~420 (2020)
46. Silverberg JI, "Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis : results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial", Br J Dermatol, 184, pp.450~463 (2021)
47. Kabashima K, "Trial of nemolizumab and topical agents for atopic dermatitis with pruritus", N Engl J Med, 383, pp.141~150 (2020)
48. Guttman-Yassky E, "GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis Recent clinical trials of new biologics for moderate to severe atopic dermatitis", J Allergy Clin Immunol, 144, pp.482~493 (2019)
49. Simpson EL, "Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis : a randomized phase 2a clinical trial", J Am Acad Dermatol, 80, pp.1013~1021 (2019)
50. Simpson EL, "Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis(JADE MONO-1) : a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial", Lancet, 396, pp.255~266 (2020)

관련 논문AI추천